Monthly Archives: September 2023

The analysis of biopharma R&D needs to be improved.

    Btobioinnovation.com  Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com       SPECIAL REPORT     The analysis of biopharma R&D needs to be improved.     When investors and financial analysts assess the yearly progress of the biopharmaceutical industry, they usually consider two main figures: the number of new drug approvals and the […]

read more